BACKGROUND: Our aim was to review Memorial Sloan-Kettering Cancer Center's experience with postoperative intensity-modulated radiotherapy (IMRT) for paranasal sinus, nasal cavity, and lacrimal gland cancer and report dosimetric measures, toxicity, and outcomes. METHODS: Between September 2000 and June 2006, 37 patients with paranasal sinus, nasal cavity, or lacrimal gland cancer underwent postoperative IMRT. Median values were as follows: prescription dose, 60 Gy (range, 50-70); PTV(D95), 99% (range, 79-101%); optic nerve Dmax, 53 Gy (range, 2-54); optic chiasm Dmax, 51Gy (range, 2-55). Acute and late toxicities were scored by Radiation Therapy Oncology Group morbidity criteria. RESULTS: Median follow-up was 28 months. Two-year local progression-free and overall survivals were 75% and 80%. No early- or late-grade 3/4 radiation-induced ophthalmologic toxicity occurred. CONCLUSIONS: Preliminary results show that adjuvant IMRT in these patients is feasible, allowed for excellent planning target volume (PTV) coverage, and minimized dose delivered to optic structures. Longer follow-up is warranted to assess the extent of late effects and outcomes.
BACKGROUND: Our aim was to review Memorial Sloan-Kettering Cancer Center's experience with postoperative intensity-modulated radiotherapy (IMRT) for paranasal sinus, nasal cavity, and lacrimal gland cancer and report dosimetric measures, toxicity, and outcomes. METHODS: Between September 2000 and June 2006, 37 patients with paranasal sinus, nasal cavity, or lacrimal gland cancer underwent postoperative IMRT. Median values were as follows: prescription dose, 60 Gy (range, 50-70); PTV(D95), 99% (range, 79-101%); optic nerve Dmax, 53 Gy (range, 2-54); optic chiasm Dmax, 51Gy (range, 2-55). Acute and late toxicities were scored by Radiation Therapy Oncology Group morbidity criteria. RESULTS: Median follow-up was 28 months. Two-year local progression-free and overall survivals were 75% and 80%. No early- or late-grade 3/4 radiation-induced ophthalmologic toxicity occurred. CONCLUSIONS: Preliminary results show that adjuvant IMRT in these patients is feasible, allowed for excellent planning target volume (PTV) coverage, and minimized dose delivered to optic structures. Longer follow-up is warranted to assess the extent of late effects and outcomes.
Authors: Ming Fan; Jung Julie Kang; Anna Lee; Dan Fan; Huili Wang; Sarin Kitpanit; Pamela Fox; Kevin Sine; Dennis Mah; Sean M McBride; Chiaojung Jillian Tsai; Nadeem Riaz; Lara A Dunn; Eric J Sherman; Loren Michel; Bhuvanesh Singh; Ian Ganly; Richard J Wong; Jay O Boyle; Marc A Cohen; Nancy Y Lee Journal: Cancer Date: 2020-02-25 Impact factor: 6.860
Authors: Alexander Chi; Nam P Nguyen; William Tse; Gill Sobremonte; Patrick Concannon; Angela Zhu Journal: J Hematol Oncol Date: 2013-01-07 Impact factor: 17.388
Authors: Alexandra D Jensen; Anna V Nikoghosyan; Christine Windemuth-Kieselbach; Jürgen Debus; Marc W Münter Journal: BMC Cancer Date: 2011-05-22 Impact factor: 4.430
Authors: Alexandra D Jensen; Anna V Nikoghosyan; Swantje Ecker; Malte Ellerbrock; Jürgen Debus; Marc W Münter Journal: Radiat Oncol Date: 2011-04-05 Impact factor: 3.481
Authors: Olena Klymenko; Anna Maria Stefanie Buchberger; Barbara Wollenberg; Klaus-Dietrich Wolff; Victoria Kehl; Stephanie E Combs; Anja Pickhard; Steffi U Pigorsch Journal: Cancers (Basel) Date: 2021-05-14 Impact factor: 6.639